RS54588B1 - Liquid nasal spray containing low-dose naltrexone - Google Patents
Liquid nasal spray containing low-dose naltrexoneInfo
- Publication number
- RS54588B1 RS54588B1 RS20160104A RSP20160104A RS54588B1 RS 54588 B1 RS54588 B1 RS 54588B1 RS 20160104 A RS20160104 A RS 20160104A RS P20160104 A RSP20160104 A RS P20160104A RS 54588 B1 RS54588 B1 RS 54588B1
- Authority
- RS
- Serbia
- Prior art keywords
- nasal spray
- containing low
- spray containing
- dose naltrexone
- liquid nasal
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Emergency Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Otolaryngology (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Farmaceutske formulacije u obliku tečnog rastvora za primenu pomoću spreja preko nazalnog puta koje sadrže naltrekson u količinama između 0.005-0.02% tež./zapr.Prijava sadrži još 5 patentnih zahteva.Pharmaceutical formulations in liquid form for nasal spray application containing naltrexone in amounts between 0.005-0.02% w / v. The application contains 5 more claims.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ITFI2010A000113A IT1400067B1 (en) | 2010-05-21 | 2010-05-21 | LIQUID NASAL SPRAY CONTAINING NALTREXONE WITH LOW DOSAGE. |
PCT/EP2011/058284 WO2011144746A2 (en) | 2010-05-21 | 2011-05-20 | Liquid nasal spray containing low-dose naltrexone |
Publications (1)
Publication Number | Publication Date |
---|---|
RS54588B1 true RS54588B1 (en) | 2016-08-31 |
Family
ID=43431069
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RS20160104A RS54588B1 (en) | 2010-05-21 | 2011-05-20 | Liquid nasal spray containing low-dose naltrexone |
Country Status (17)
Country | Link |
---|---|
US (1) | US20130059876A1 (en) |
EP (1) | EP2574167B1 (en) |
CN (1) | CN102905689A (en) |
BR (1) | BR112012029595A2 (en) |
CA (1) | CA2800094C (en) |
DK (1) | DK2574167T3 (en) |
ES (1) | ES2564936T3 (en) |
HR (1) | HRP20160187T1 (en) |
HU (1) | HUE026994T2 (en) |
IT (1) | IT1400067B1 (en) |
MX (1) | MX2012013380A (en) |
NZ (1) | NZ604417A (en) |
PL (1) | PL2574167T3 (en) |
RS (1) | RS54588B1 (en) |
RU (1) | RU2552786C2 (en) |
SI (1) | SI2574167T1 (en) |
WO (1) | WO2011144746A2 (en) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2065038A1 (en) | 2007-11-30 | 2009-06-03 | Pharnext | New therapeutic approaches for treating Charcot-Marie-Tooth disease |
EP2263665A1 (en) | 2009-06-02 | 2010-12-22 | Pharnext | New compositions for treating CMT and related disorders |
US9393241B2 (en) | 2009-06-02 | 2016-07-19 | Pharnext | Compositions for treating CMT and related disorders |
JP6300906B2 (en) | 2013-06-05 | 2018-03-28 | ファーネクストPharnext | Stable oral solution for active pharmaceutical ingredients (API) |
CA2875384A1 (en) | 2013-12-20 | 2015-06-20 | AntiOP, Inc. | Intranasal naloxone compositions and methods of making and using same |
US10722510B2 (en) | 2014-07-08 | 2020-07-28 | Hikma Pharmaceuticals Usa Inc. | Liquid naloxone spray |
WO2016007729A1 (en) * | 2014-07-09 | 2016-01-14 | Lightlake Therapeutics Inc. | Co-packaged drug products |
WO2017141104A2 (en) * | 2016-02-18 | 2017-08-24 | Immune Therapeutics, Inc. | Method for inducing a sustained immune response |
US10383870B2 (en) | 2016-06-10 | 2019-08-20 | Pharnext | Early treatment of CMT disease |
US20180092839A1 (en) * | 2016-10-03 | 2018-04-05 | Lance L. Gooberman | Medicated spray for treatment of substance abuse, overdose, addiction and impulse control disorders |
EP3906934A1 (en) * | 2020-05-06 | 2021-11-10 | PVP Labs PTE. Ltd. | Application of dalargin for the prevention of viral respiratory infections and prevention of the development of complications during viral respiratory infections |
US11752143B2 (en) | 2020-12-31 | 2023-09-12 | Soin Therapeutics Llc | Methods of using low dose naltrexone to treat chronic pain |
CN118021709A (en) * | 2022-11-07 | 2024-05-14 | 深圳善康医药科技股份有限公司 | Naltrexone in-situ gel nasal spray and preparation method and application thereof |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9908921D0 (en) * | 1999-04-19 | 1999-06-16 | Britannia Pharmaceuticals Ltd | Spray dispenser for opiod antagonists |
WO2002011778A1 (en) * | 2000-05-10 | 2002-02-14 | University Of Kentucky Research Foundation | System and method for intranasal administration of opioids |
WO2003002071A2 (en) * | 2001-06-29 | 2003-01-09 | Lewandowski Leon J | Individualized addiction cessation therapy |
RU2224518C1 (en) * | 2003-02-10 | 2004-02-27 | Дулькис Мария Дмитриевна | Naltrexone liquid medicinal form |
US20070212307A1 (en) * | 2006-02-10 | 2007-09-13 | Daniel Wermeling | Pharmaceutical Compositions Comprising an Opioid Receptor Antagonist and Methods of Using Same |
WO2009040595A1 (en) * | 2007-09-28 | 2009-04-02 | Wockhardt Research Centre | Multi-dose pharmaceutical composition of analgesic for nasal administration |
EP2266563A1 (en) * | 2009-06-11 | 2010-12-29 | Charité-Universitätsmedizin Berlin (Charité) | Use of opioid receptor antagonists for acute treatment of paraphilic arousal states |
-
2010
- 2010-05-21 IT ITFI2010A000113A patent/IT1400067B1/en active
-
2011
- 2011-05-20 DK DK11726367.3T patent/DK2574167T3/en active
- 2011-05-20 RU RU2012155711/15A patent/RU2552786C2/en active
- 2011-05-20 BR BR112012029595A patent/BR112012029595A2/en active Search and Examination
- 2011-05-20 WO PCT/EP2011/058284 patent/WO2011144746A2/en active Application Filing
- 2011-05-20 CA CA2800094A patent/CA2800094C/en not_active Expired - Fee Related
- 2011-05-20 PL PL11726367T patent/PL2574167T3/en unknown
- 2011-05-20 US US13/698,128 patent/US20130059876A1/en not_active Abandoned
- 2011-05-20 HU HUE11726367A patent/HUE026994T2/en unknown
- 2011-05-20 NZ NZ604417A patent/NZ604417A/en not_active IP Right Cessation
- 2011-05-20 ES ES11726367.3T patent/ES2564936T3/en active Active
- 2011-05-20 SI SI201130746A patent/SI2574167T1/en unknown
- 2011-05-20 CN CN2011800249945A patent/CN102905689A/en active Pending
- 2011-05-20 MX MX2012013380A patent/MX2012013380A/en not_active Application Discontinuation
- 2011-05-20 RS RS20160104A patent/RS54588B1/en unknown
- 2011-05-20 EP EP11726367.3A patent/EP2574167B1/en active Active
-
2016
- 2016-02-23 HR HRP20160187TT patent/HRP20160187T1/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2011144746A3 (en) | 2012-02-02 |
CA2800094C (en) | 2018-05-29 |
IT1400067B1 (en) | 2013-05-17 |
MX2012013380A (en) | 2013-02-11 |
DK2574167T3 (en) | 2016-03-07 |
EP2574167A2 (en) | 2013-04-03 |
NZ604417A (en) | 2014-03-28 |
RU2552786C2 (en) | 2015-06-10 |
HRP20160187T1 (en) | 2016-04-08 |
CN102905689A (en) | 2013-01-30 |
WO2011144746A2 (en) | 2011-11-24 |
RU2012155711A (en) | 2014-06-27 |
HUE026994T2 (en) | 2016-08-29 |
SI2574167T1 (en) | 2016-05-31 |
PL2574167T3 (en) | 2016-07-29 |
ITFI20100113A1 (en) | 2011-11-22 |
US20130059876A1 (en) | 2013-03-07 |
ES2564936T3 (en) | 2016-03-30 |
CA2800094A1 (en) | 2011-11-24 |
EP2574167B1 (en) | 2015-12-16 |
AU2011254554A1 (en) | 2013-01-10 |
BR112012029595A2 (en) | 2016-12-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RS54588B1 (en) | Liquid nasal spray containing low-dose naltrexone | |
MX2021006035A (en) | Stable cannabinoid formulations. | |
HK1254470A1 (en) | 3' equatorial-fluorine-substituted neuraminidase inhibitor compounds, compositions and methods for the use thereof as anti-virals | |
MX2013002048A (en) | Conjugates, particles, compositions, and related methods. | |
PH12015501738A1 (en) | Androgen receptor modulators and uses thereof | |
PH12014501351B1 (en) | Fluorinated estrogen receptor modulators and uses thereof | |
GB201106750D0 (en) | Novel compounds | |
IL232515A0 (en) | Nadph oxidase 4 inhibitors and pharmaceutical compositions containing the same | |
MY160456A (en) | Benzodiazepine bromodomain inhibitor | |
MY181190A (en) | Improved adenovirus formulations | |
EP2569330A4 (en) | Chlorotoxin variants, conjugates, and methods for their use | |
NZ709958A (en) | Enhanced stability of novel liquid compositions | |
UA98839C2 (en) | N,n-disubstituted aminoalkylbiphenyl antagonists of prostaglandin d2 receptors | |
SI2739615T1 (en) | Phenyl-3-aza-bicyclo(3.1.0)hex-3-yl-methanones and the use thereof as medicament | |
MX2014010537A (en) | Liver x receptor (lxr) modulators for the treatment of dermal diseases, disorders and conditions. | |
NZ702930A (en) | Racecadotril liquid compositions | |
MY157673A (en) | Pharmaceutical compositions comprising hydromorphone and naloxone | |
MX2013013649A (en) | Quinone compounds for treating ape1 mediated diseases. | |
UA110979C2 (en) | Liquid pharmaceutical formulation comprising nitisinone | |
MX2015006223A (en) | Pharmaceutical compositions of cetp inhibitors. | |
GB201302343D0 (en) | Pharmaceutical compositions comprising 15-OHEPA and methods for using the same | |
RS52461B (en) | Flupentixol compositions | |
IT1400837B1 (en) | METHOD FOR THE PREPARATION AND USE OF ENRICHED BIOCIDES IN ACTIVE RADICALS BEFORE USE. | |
MY165088A (en) | Pharmaceutical compositions comprising alisporivir | |
MX2016002930A (en) | Liver x receptor (lxr) modulators. |